- Home
- PEN vs ARWR Comparison
PEN vs ARWR Comparison
Compare PEN & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEN | ARWR |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 9.6B |
| IPO Year | 2015 | 1993 |
Fundamental Metrics
Financial Performance| Metric | PEN | ARWR |
|---|---|---|
| Price | $312.60 | $70.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $311.25 | $60.70 |
| AVG Volume (30 Days) | 493.7K | ★ 3.3M |
| Earning Date | 11-05-2025 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 367.34 | N/A |
| EPS | ★ 4.14 | N/A |
| Revenue | ★ $1,333,798,000.00 | $829,448,000.00 |
| Revenue This Year | $16.77 | N/A |
| Revenue Next Year | $14.12 | N/A |
| P/E Ratio | $75.40 | ★ N/A |
| Revenue Growth | 14.61 | ★ 23258.15 |
| 52 Week Low | $221.26 | $9.57 |
| 52 Week High | $315.01 | $72.36 |
Technical Indicators
Market Signals| Indicator | PEN | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 67.99 | 76.76 |
| Support Level | $286.75 | $60.29 |
| Resistance Level | $303.00 | $72.36 |
| Average True Range (ATR) | 8.69 | 5.14 |
| MACD | 0.81 | 1.44 |
| Stochastic Oscillator | 92.00 | 92.98 |
Price Performance
Historical ComparisonAbout PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.